Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROACT Xa
NCT04142658Phase 3Terminated
- Sponsor
- Artivion
- Start
- May 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apixaban in thromboembolism and prosthetic valve thrombosis (PVT) (2 arms), sponsored by Artivion. Primary endpoints: Composite of Valve Thrombosis and Valve-related Thromboembolism and Major Bleeding. Started May 2020; status: terminated.
02
Drugs
apixaban
03
Conditions
thromboembolismprosthetic valve thrombosis (PVT)
Beyond the preview
Go deeper on NCT04142658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142658.